ChemoCentryx (CCXI) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. CMG
7. TENB
8. BIIB
9. KLAC
10. ETSY

Go back to ChemoCentryx (CCXI) Reports In-Line Q4 EPS

ChemoCentryx Reports Fourth Quarter 2014 Financial Results and Provides Corporate Update

March 12, 2015 4:05 PM EDT

-- Presentation of CCR2 inhibitor CCX140 Phase II Diabetic Nephropathy results anticipated at upcoming medical meetings --

-- Recruitment projections to complete enrollment in C5aR inhibitor CCX168 CLEAR Phase II ANCA-associated vasculitis clinical trial remain on track --

-- Initial data anticipated from other pipeline programs, including CCX168 in atypical Hemolytic Uremic Syndrome, CCX872 in non-resectable pancreatic cancer, and other pipeline programs --

-- Conference Call Today at 5:00 p.m. Eastern Time --

MOUNTAIN VIEW, Calif., March 12,... More